



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Lartruvo (olaratumab)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: <input type="checkbox"/> Lartruvo Dose: _____ Frequency of therapy: _____ Duration of therapy: _____ ICD10: _____ Will this medication be given concurrently with other agents? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please specify: What is your patient's current height? _____ What is your patient's current weight? _____					
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Other (please specify): _____ <div style="text-align: right; margin-top: 10px;"> <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Home Health / Home Infusion vendor <i>**Cigna's nationally preferred specialty pharmacy</i> </div> <p><small>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</small></p>					
Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____					
Is the patient a candidate for home infusion? Yes <input type="checkbox"/> No <input type="checkbox"/> Does the physician have an in-office infusion site? Yes <input type="checkbox"/> No <input type="checkbox"/>					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
What is your patient's diagnosis? <input type="checkbox"/> soft tissue sarcoma <input type="checkbox"/> uterine sarcoma			<input type="checkbox"/> other (please specify): _____		
Clinical Information <p style="text-align: center;">**This drug requires supportive documentation of beneficial response for continuation. Supportive documentation for continued therapy with beneficial response must be attached with this request.**</p> Is this a new start or continuation of therapy with Lartruvo? <input type="checkbox"/> new start <input type="checkbox"/> continued therapy (if continued therapy) Has there been a documented beneficial response to use of Lartruvo? Please provide supportive documentation. Yes <input type="checkbox"/> No <input type="checkbox"/> (if continued therapy) How many cycles of chemotherapy has your patient already received? <input type="checkbox"/> 1-7 cycles <input type="checkbox"/> 8 cycles or more (if STS) Is your patient's cancer histological subtype appropriate for treatment with either doxorubicin or epirubicin? Yes <input type="checkbox"/> No <input type="checkbox"/> (if yes) Is/Was your patient being treated with doxorubicin as well as Lartruvo for the first 8 cycles of chemotherapy? Yes <input type="checkbox"/> No <input type="checkbox"/> (if STS) Is your patient a candidate for curative radiotherapy or surgery? Yes <input type="checkbox"/> No <input type="checkbox"/>					

(if uterine sarcoma) Is/Was your patient being treated with doxorubicin as well as Lartruvo for the first 8 cycles of chemotherapy? Yes No

(if uterine sarcoma) Has your patient had a radiologically isolated vaginal/pelvic recurrence? Yes No

(if no recurrence) Does your patient have isolated or disseminated metastases? Yes No

(if no metastases) Has your patient had a total hysterectomy with or without bilateral salpingo-oophorectomy? Yes No

(if no hysterectomy) Is your patient a candidate for curative radiotherapy or surgery? Yes No

Additional pertinent information (including prior therapy, disease stage, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermy meds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v030119

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005